-
Je něco špatně v tomto záznamu ?
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
V. Kozlova, A. Ledererova, A. Ladungova, H. Peschelova, P. Janovska, A. Slusarczyk, J. Domagala, P. Kopcil, V. Vakulova, J. Oppelt, V. Bryja, M. Doubek, J. Mayer, S. Pospisilova, M. Smida,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
Public Library of Science (PLoS)
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2006-12-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-10-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2008-01-01
Nursing & Allied Health Database (ProQuest)
od 2006-12-01
Health & Medicine (ProQuest)
od 2006-12-01
Public Health Database (ProQuest)
od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- aktiny metabolismus MeSH
- antigeny CD20 genetika metabolismus fyziologie MeSH
- B-buněčný lymfom metabolismus patologie MeSH
- B-lymfocyty patologie fyziologie MeSH
- buněčná adheze fyziologie MeSH
- genový knockdown MeSH
- leukemie B-buněčná metabolismus patologie MeSH
- lidé MeSH
- multimerizace proteinu fyziologie MeSH
- myši inbrední NOD MeSH
- myši SCID MeSH
- myši transgenní MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- pohyb buněk fyziologie MeSH
- polymerizace MeSH
- receptory antigenů B-buněk metabolismus MeSH
- signální transdukce imunologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Surface protein CD20 serves as the critical target of immunotherapy in various B-cell malignancies for decades, however its biological function and regulation remain largely elusive. Better understanding of CD20 function may help to design improved rational therapies to prevent development of resistance. Using CRISPR/Cas9 technique, we have abrogated CD20 expression in five different malignant B-cell lines. We show that CD20 deletion has no effect upon B-cell receptor signaling or calcium flux. Also B-cell survival and proliferation is unaffected in the absence of CD20. On the contrary, we found a strong defect in actin cytoskeleton polymerization and, consequently, defective cell adhesion and migration in response to homeostatic chemokines SDF1α, CCL19 and CCL21. Mechanistically, we could identify a reduction in chemokine-triggered PYK2 activation, a calcium-activated signaling protein involved in activation of MAP kinases and cytoskeleton regulation. These cellular defects in consequence result in a severely disturbed homing of B cells in vivo.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Experimental Biology Faculty of Science Masaryk University Brno Czech Republic
Department of Immunology Medical University of Warsaw Warsaw Poland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023098
- 003
- CZ-PrNML
- 005
- 20201214125253.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0229170 $2 doi
- 035 __
- $a (PubMed)32210425
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kozlova, Veronika $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 245 10
- $a CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells / $c V. Kozlova, A. Ledererova, A. Ladungova, H. Peschelova, P. Janovska, A. Slusarczyk, J. Domagala, P. Kopcil, V. Vakulova, J. Oppelt, V. Bryja, M. Doubek, J. Mayer, S. Pospisilova, M. Smida,
- 520 9_
- $a Surface protein CD20 serves as the critical target of immunotherapy in various B-cell malignancies for decades, however its biological function and regulation remain largely elusive. Better understanding of CD20 function may help to design improved rational therapies to prevent development of resistance. Using CRISPR/Cas9 technique, we have abrogated CD20 expression in five different malignant B-cell lines. We show that CD20 deletion has no effect upon B-cell receptor signaling or calcium flux. Also B-cell survival and proliferation is unaffected in the absence of CD20. On the contrary, we found a strong defect in actin cytoskeleton polymerization and, consequently, defective cell adhesion and migration in response to homeostatic chemokines SDF1α, CCL19 and CCL21. Mechanistically, we could identify a reduction in chemokine-triggered PYK2 activation, a calcium-activated signaling protein involved in activation of MAP kinases and cytoskeleton regulation. These cellular defects in consequence result in a severely disturbed homing of B cells in vivo.
- 650 _2
- $a aktiny $x metabolismus $7 D000199
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antigeny CD20 $x genetika $x metabolismus $x fyziologie $7 D018951
- 650 _2
- $a B-lymfocyty $x patologie $x fyziologie $7 D001402
- 650 _2
- $a buněčná adheze $x fyziologie $7 D002448
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a pohyb buněk $x fyziologie $7 D002465
- 650 _2
- $a genový knockdown $7 D055785
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukemie B-buněčná $x metabolismus $x patologie $7 D015448
- 650 _2
- $a B-buněčný lymfom $x metabolismus $x patologie $7 D016393
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední NOD $7 D016688
- 650 _2
- $a myši SCID $7 D016513
- 650 _2
- $a myši transgenní $7 D008822
- 650 _2
- $a polymerizace $7 D058105
- 650 _2
- $a multimerizace proteinu $x fyziologie $7 D055503
- 650 _2
- $a receptory antigenů B-buněk $x metabolismus $7 D011947
- 650 _2
- $a signální transdukce $x imunologie $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ledererova, Aneta $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Ladungova, Adriana $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Peschelova, Helena $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Janovska, Pavlina $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Slusarczyk, Aleksander $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
- 700 1_
- $a Domagala, Joanna $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland.
- 700 1_
- $a Kopcil, Pavel $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Vakulova, Viera $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Oppelt, Jan $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Bryja, Vitezslav $u Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Doubek, Michael $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Mayer, Jiri $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Pospisilova, Sarka $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Smida, Michal $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Medical Faculty of Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 15, č. 3 (2020), s. e0229170
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32210425 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214125252 $b ABA008
- 999 __
- $a ok $b bmc $g 1595417 $s 1113774
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 15 $c 3 $d e0229170 $e 20200325 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20201125